To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer Clinical Trial

Official title:

Phase Ib/II Clinical Study of TQB3823 Tablets Combined With Abiraterone Acetate Tablets and Prednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05405439
• Other study ID #: TQB3823-Ib/II-01
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: August 25, 2022
• Est. completion date: July 19, 2023

Study information

• Verified date: November 2023
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

Description:

This is a two-phase, open-label Phase Ib clinical trial. The first phase plans to enroll 6-12 patients as two cohorts to explore the safety and of TQB3823 tablets combined with abiraterone and prednisone and the recommended dose of phase II of TQB3823. Subjects involved in cohort one accepts TQB3823 treatment during cycle one and then TQB3823 combined with abiraterone and prednisone from cycle two till the disease progression. The second phase plans to enroll a total of 40-60 subjects, aiming to evaluate the safety and efficacy of TQB3823 tablets combined with abiraterone and prednisone.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 39
• Est. completion date: July 19, 2023
• Est. primary completion date: July 19, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Male patients aged 18 to 85.
• Subjects with pathologically proven with prostate adenocarcinoma.
• Metastatic disease confirmed by imaging (eg, bone scan and CT/MRI).
• The patient's serum testosterone level at the screening visit was = 1.73 nmol/L (50 ng/dL). Patients who did not undergo bilateral orchiectomy required continued ADT [gonadotropin-releasing hormone analog (LHRHa, agonist/antagonist)] treatment throughout the study period.
• Disease progression during consecutive androgen deprivation therapy (ADT), defined at

study entry, as meeting one or more of the following criteria:

1. At least two consecutive PSA elevations separated by at least 1 week, the last result must be at least 1.0 ng/mL.

2. Soft tissue lesion progression as assessed by RECIST 1.1 with or without PSA progression.

3. Bone disease progression assessed by PCWG3, i.e., =2 new lesions detected on bone scan, =2 new bone lesions other than those previously assessed on reassessment at least 8 weeks later, with =2 previously assessed bone lesions still exist, regardless of PSA progression.

• Patients must discontinue all prior cancer therapy (except ADT and bone loss prophylaxis) and have recovered to = Grade 1 or baseline (according to the Common Terminology Criteria for Adverse Events) prior to first dose of all acute toxic effects of prior therapy or surgery Version 5.0 [CTCAE v 5.0]), with the exception of alopecia and peripheral neuropathy, and the washout period since the last prior

systemic or radiation therapy was as follows:

1. At least 4 weeks must have elapsed since enrollment with 5-alpha reductase inhibitors (eg, dutasteride, finasteride), estrogen, and cyproterone.

2. At least 4 weeks must have elapsed from major surgery or radiation therapy to enrollment?

• Laboratory indicators meet the requirements.

Exclusion Criteria:

• For subjects with brain metastases with symptoms or symptom control for less than 1 month, screening for CNS metastases at baseline is not required unless there are signs and/or symptoms of CNS involvement.
• Subjects who have developed or is currently suffering from other malignancies within 3 years, except for cured skin basal cell carcinoma and cervical carcinoma in situ.
• Subjects who have accepted botanicals (such as saw palmetto) that may lower PSA levels within 4 weeks before the first dose.
• Subjects who have accepted oral targeted drugs within 5 drug half-lives from the first dose (calculated from the end of the last treatment).
• Subjects who have not recovered to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 due to the adverse event of prior therapy.
• Subjects who have previously accepted CYP17 enzyme inhibitors (including drugs such as abiraterone, TAK-700, TOK-001, and ketoconazole, ect.,) or second generation androgen receptor inhibitors (including enzalutamide, apalutamide, darolutamide , etc.) (mHSPC, nmCRPC stage).

1. The study accept patients who received McRpc-based chemotherapy with CYP17 inhibitors other than abiraterone or second-generation androgen receptor inhibitors or paclitaxel for less than 3 months without disease progression, However, 4 weeks or 5 half-life washing out period is required (whichever is longer).

2. Patients who received abiraterone in the mCRPC phase for less than 3 months and did not progress (no need to stop elution) are allowed in the study, but cannot be enrolled in the phase I cohort of a single drug population in this study.

3. Patients who received ADT+ paclitaxel chemotherapy, ADT+ 1st generation androgen receptor inhibitors (e.g. Flutamide, bicalutamide, nilutamide, etc.), ADT+ERBT (external radiation therapy) in mHSPC phase will be acceptable in the study, provided that they met the exclusion criteria 2.

• Subjects who receive medications known to be potent inhibitors of cytochrome P450 3A4 (CYP3A4) or potent or moderate inducers and unable to discontinue these medications or switch to another for at least 5 half-lives prior to initiation of study medication different medicines.
• Subjects who suffer from contraindications to prednisone (corticosteroid) use, such as active systemic infection (e.g. bacterial infection requiring intravenous antibiotics at initiation of study treatment, fungal infection, or detectable viral infection requiring systemic therapy ) or viral load (e.g. known HIV positive or known active hepatitis B or C (e.g. hepatitis B surface antigen positive). Screening for contraindications other than HIV/HBV and HCV is not required to determine eligibility.
• Subjects with history of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on a chest CT scan during screening.
• Subjects with any chronic condition requiring corticosteroid treatment at doses greater than "Prednisone 5mg, BID";

Related Conditions & MeSH terms

• Metastatic Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• TQB3823 tablets
TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
• Abiraterone acetate tablets
Abiraterone acetate tablet is an inhibitor of cytochrome P450 17(CYP17)
• prednisone acetate tablets
Prednisone acetate tablet is a kind of glucocorticoids

Locations

Country	Name	City	State
China	The First Hospital of Peking University	Beijing	Beijing
China	Hunan Cancer Hospital	Changsha	Hunan
China	Sichuan Provincial People's Hospital	Chengdu	Sichuan
China	West China Hospital,Sichuan University	Chengdu	Sichuan
China	Chongqing Cancer Hospital	Chongqing	Chongqing
China	The Southwest Hospitai of Amu	Chongqing	Chongqing
China	Sun Yat-Sun University Cancer Prevertion and Treatment Center	Guangzhou	Guangdong
China	Affiliated Cancer Hospital of Harbin Medical University	Harbin	Heilongjiang
China	Shandong Cancer Hospital	Jinan	Shandong
China	Second Affiliated Hospital of Kunming Medical University	Kunming	Yunnan
China	The First Affiliated Hospital of Kunming Medical University	Kunming	Yunnan
China	The Second Hospital of Harbin Medical University	Lanzhou	Gansu
China	The Affiliated Hospital of Southwest Medical University	Luzhou	Sichuan
China	Mianyang Central Hospital	Mianyang	Sichuan
China	Jiangsu Province Hospital	Nanjing	Jiangsu
China	The First Affiliated Hospital of Guangxi Medical University	Nanning	Guangxi
China	Qingyuan People's Hospital	Qingyuan	Guangdong
China	Huadong Hospital Affiliated to Fudan University	Shanghai	Shanghai
China	Shengjing Hospital Affiliated to China Medical University	Shenyang	Liaoning
China	Cancer Hospital of Tianjin Medical University	Tianjin	Tianjin
China	The First Affiliated Hospital of Wenzhou Medical Univerity	Wenzhou	Zhejiang
China	The First Affiliated Hospital of The Chinese People's Liberation Army Air Force Military Medical University	Xi'an	Shanxi
China	Zigong Fourth People's Hospital	Zigong	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT)	The relevant adverse reactions occurred within the first cycle	Up to 4 weeks
Primary	Recommended phase II dose (RP2D)	The dose of TQB3823 tablet which is recommended to use during phase II clinical trial	Up to 8 weeks
Primary	The ratio of subject radiographic progression-free survival for 12 months	Proportion of subjects without disease progression assessed by radiology within 12 months	For 12 months
Primary	Adiographic progression-free survival (rPFS)	rPFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause evaluated by radiological examination	Up to 24 months
Secondary	The ratio of subject radiographic progression-free survival for 12 months	Proportion of subjects without disease progression assessed by radiology within 6 months	For 6 months
Secondary	The ratio of prostate specific antigen (PSA) reduction	Proportion of subjects with reduction of PSA	Up to 24 months
Secondary	Overall response rate (ORR) based on 2014 Lugano	Percentage of participants achieving complete response (CR) and partial response (PR).	Up to 24 months
Secondary	Overall survival (OS)	OS defined as the time from randomization until the death from any cause	Up to death
Secondary	Clinical benefit rate (CBR)	Proportion of subjects with clinical benefit	Up to 24 months
Secondary	Duration of Response (DOR)	The time when the participants first achieved CR or PR to disease progression or death from any cause.	Up to 24 months
Secondary	time to bone-related event	Time to progression of bone disease in subjects	Up to 24 months
Secondary	Time to PSA progression	Time to raise of PSA in subjects	Up to 24 months
Secondary	Peak time (Tmax)	The time to peak concentration	Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days)
Secondary	Peak concentration (Cmax)	Maximum plasma drug concentration	Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days)
Secondary	Half-life /T1/2	The time it takes for the drug's concentration in the body to drop by half	Cycle 1 day 1 and cycle 1 day 28 Before administration, and 1, 2, 4, 6, 8, 11, 12, 24 hours after administration. Cycle 1 day 14 before administration,(each cycle is 28 days)
Secondary	Adverse event rate	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).	Baseline up to 96 weeks
Secondary	Adverse event rate	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).	Baseline up to 24 months